Latest news with #ABT
Globe and Mail
a day ago
- Business
- Globe and Mail
ABT's i-STAT TBI Test Receives Approval in Canada: Stock to Rise?
Abbott Laboratories ABT recently received Health Canada approval for the i-STAT TBI test cartridge for use with whole blood. It is designed to help clinicians assess suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes. The latest approval expands the company's TBI test offerings, which include the i-STAT TBI Plasma test, and the ARCHITECT and Alinity i lab test (serum and plasma). ABT Stock's Likely Trend Following the News Following the announcement, Abbott's shares edged down 1.2%, finishing at $134.01 on Monday. On a positive note, Abbott's accelerated investments in the R&D pipeline are yielding positive results. Hence, we expect the market sentiment toward ABT stock to turn positive surrounding the latest approval. Abbott holds a market capitalization of $230.37 billion. The company's earnings yield of 3.9% surpasses the industry's 0.6%. ABT delivered an average earnings beat of 1.6% in the trailing four quarters. About Abbott's i-STAT TBI Test Cartridge Usage For decades, standard TBI assessment has remained the same, with doctors leveraging tools, such as the Canadian CT Head Rule, which uses the Glasgow Coma Scale to detect brain tissue damage or lesions. However, the whole blood test on a portable instrument helps clinicians evaluate patients 18 years of age and older with suspected mild traumatic brain injury (mTBI), commonly known as a concussion. The blood test provides objective information and helps remove the ambiguity of a standard concussion assessment. The i-STAT TBI test cartridge can be used to help evaluate patients up to 24 hours after injury. The i-STAT TBI test cartridge with the i-STAT Alinity System requires a small venous blood sample. The cartridge is then inserted into the portable i-STAT Alinity instrument. The test measures two brain-specific biomarkers, ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), which are released into the blood stream during a significant brain injury. Testing for these two biomarkers following an injury can provide essential and objective information about a patient's condition and help healthcare providers choose an appropriate treatment plan. Industry Prospect Favors ABT Per a report by Brain Injury Canada, an estimated 165 million Canadians will experience a TBI in 2025. Likewise, the Government of Canada released a report stating that each year more than 20 million people are hospitalized for TBI in the country, and the injury can range from mild to severe and include concussions. Even a mild form of TBI can have long-term consequences. Among all types of TBIs, concussions are the most common, accounting for approximately 80-95% of such injuries. Another Development by Abbott Last month, Abbott received Food and Drug Administration ('FDA') approval for its Tendyne transcatheter mitral valve replacement (TMVR) system. The Tendyne system replaces mitral valves that are not functioning properly due to severe mitral annular calcification (MAC). ABT Stock Price Performance Over the past year, Abbott's shares have risen 27.3%, surpassing the industry 's 8.4% growth. ABT's Zacks Rank and Key Picks Abbott currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Align Technology ALGN, Hims & Hers Health HIMS and Cencora COR. Align Technology has an estimated long-term earnings growth rate of 11.2% compared with the industry's 9.9%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 3.4%. Its shares have lost 27.7% compared with the industry's 3.3% decline in the past year. ALGN sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. Hims & Hers Health, currently carrying a Zacks Rank #2 (Buy), has an earnings yield of 1.3% against the industry's -10.1%. Shares of the company have surged 129.7% compared with the industry's 35.9% gain. HIMS' earnings surpassed estimates in two of the trailing four quarters, matched once and missed in the other, the average surprise being 2.8%. Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry's 3.8%. Shares of the company have rallied 25.9% against the industry's 14.4% decline. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Cencora, Inc. (COR): Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Yahoo
2 days ago
- Business
- Yahoo
Leerink Partners Begins Coverage on ABT
Abbott Laboratories (NYSE:ABT) is one of Best Dividend Stocks to Buy for Dependable Growth. The company is a Dividend King with 53 consecutive years of dividend growth. Its five-year average annual dividend growth rate sits at nearly 11%. It pays a quarterly dividend of $0.59 per share and has a dividend yield of 1.78%, as of June 17. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Leerink Partners has initiated coverage of the medical devices company, assigning it a hold-equivalent rating along with a target price of $143. This target suggests an upside of less than 6% from the stock's closing price on Friday. Although Abbott Laboratories (NYSE:ABT) is recognized for its strong industry position, Leerink's analysts mentioned that they think 'potential upside growth drivers and strong execution' are mostly already reflected in the company's 'stock at current peak valuation levels,' and they do not see any significant near-term catalysts. Abbott Laboratories (NYSE:ABT) recently received positive news from Canada, where the government approved a rapid blood test designed to assist clinicians in evaluating suspected concussions. Although this may not have an immediate significant impact, it's an intriguing product with potential applications, such as at sporting events. Abbott Laboratories (NYSE:ABT) is an international healthcare company that develops, produces, and markets a broad variety of health-related products. The stock has surged by over 16% since the start of 2025. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.
New York Post
2 days ago
- Entertainment
- New York Post
How much are tickets for Gillian Murphy's final American Ballet performances?
Vivid Seats is the New York Post's official ticketing partner. We may receive revenue from this partnership for sharing this content and/or when you make a purchase. Featured pricing is subject to change. There are few experiences in New York more transcendent than an evening with the American Ballet Theatre at the Metropolitan Opera House, where performances unfold beneath glittering Swarovski chandeliers, surrounded by red velvet carpets and the grandeur of Lincoln Center. And, from now until July 19, productions of 'Woolf Works,' 'Giselle,' 'Sylvia,' 'The Winter's Tale' and 'Swan Lake' are running at the venerable venue. These performances will be notable because Principal Dancer Gillian Murphy will take her final bow with the company, marking the end of an exquisite, era-defining career that has captivated audiences around the world. Expect standing ovations and tears as she dances her swan song on Friday, July 18. In addition to Murphy, the joyful and energetic Skylar Brandt and award-winning Herman Cornejo are also slated to serenade the stage. The two are known for performing with such effortless precision that they bring fairytales of yesteryear to vivid technicolor life with ease. While the spotlight often falls on the dancers, the American Ballet Theatre's resident orchestra deserves its own round of applause as well. In 'Swan Lake,' listen for the expressive violin solos from concertmaster Kobi Malkin and the rich, emotive cello passages by principal cellist Jonathan Spitz, capturing both the devilish and mournful tones of the lead swan. Later down the road, the ABT's fall schedule will feature yet another bittersweet milestone when Misty Copeland delivers her final farewell at the Fall Gala on Oct. 22. If you'd like to plié on over to any of the programs listed above, tickets are available for most American Ballet Theatre summer shows on Vivid Seats. Given the prestige on hand, some are shockingly affordable, too. At the time of publication, the lowest price we could find for any one ABT program was $48 including fees on Vivid Seats. Other evenings at the ballet start anywhere from $56 to $148 including fees. $148 including fees is the best price we could find on tickets to see Murphy's last performance. For more information, our team has everything you need to know and more about the 2025 American Ballet Theatre summer season below. All prices listed above are subject to fluctuation. American Ballet Theatre summer 2025 tickets As of now, 34 performances remain on ABT's Metropolitan Opera House schedule for the season. We've listed all of them by show name, date, start time and cheapest tickets available here: American Ballet Theatre summer 2025 dates Ticket prices start at 'Woolf Works' Thursday, July 19 at 7:30 p.m. $82 (including fees) 'Woolf Works' Friday, July 20 at 7:30 p.m. $70 (including fees) 'Giselle' Saturday, June 21 at 2 p.m. $78 (including fees) 'Giselle' Saturday, June 21 at 7:30 p.m.56 $83 (including fees) 'Giselle' Monday, June 23 at 7:30 p.m. $56 (including fees) 'Giselle' Tuesday, June 24 at 7:30 p.m. $64 (including fees) 'Giselle' Wednesday, June 25 at 2 p.m. $61 (including fees) 'Giselle' Wednesday, June 25 at 7:30 p.m. $56 (including fees) 'Giselle' Thursday, June 26 at 7:30 p.m. $61 (including fees) 'Giselle' Friday, June 27 at 7:30 p.m. $60 (including fees) 'Giselle' Saturday, June 28 at 2 p.m. $48 (including fees) 'Giselle' Saturday, June 28 at 7:30 p.m. $57 (including fees) 'The Winter's Tale' Tuesday, July 1 at 7:30 p.m. $66 (including fees) 'The Winter's Tale' Wednesday, July 2 at 2 p.m. $63 (including fees) 'The Winter's Tale' Wednesday, July 2 at 7:30 p.m. $64 (including fees) 'The Winter's Tale' Thursday, July 3 at 7:30 p.m. $64 (including fees) 'The Winter's Tale' Friday, July 4 at 2 p.m. $61 (including fees) 'The Winter's Tale' Saturday, July 5 at 2 p.m. $64 (including fees) 'The Winter's Tale' Saturday, July 5 at 7:30 p.m. $64 (including fees) 'Sylvia' Tuesday, July 8 at 7:30 p.m. $64 (including fees) 'Sylvia' Wednesday, July 9 at 2 p.m. $78 (including fees) 'Sylvia' Wednesday, July 9 at 7:30 p.m. $59 (including fees) 'Sylvia' Thursday, July 10 at 7:30 p.m. $60 (including fees) 'Sylvia' Friday, July 11 at 7:30 p.m. $64 (including fees) 'Sylvia' Saturday, July 12 at 2 p.m. $63 (including fees) 'Sylvia' Saturday, July 12 at 7:30 p.m. $64 (including fees) 'Swan Lake' Monday, July 14 at 7:30 p.m. $69 (including fees) 'Swan Lake' Tuesday, July 15 at 7:30 p.m. $61 (including fees) 'Swan Lake' Wednesday, July 16 at 2 p.m. $66 (including fees) 'Swan Lake' Wednesday, July 16 at 7:30 p.m. $62 (including fees) 'Swan Lake' Thursday, July 17 at 7:30 p.m. $71 (including fees) 'Swan Lake' Friday, July 18 at 7:30 p.m. $148 (including fees) 'Swan Lake' Saturday, July 19 at 2 p.m. $71 (including fees) 'Swan Lake' Saturday, July 19 at 7:30 p.m. $58 (including fees) (Note: The New York Post confirmed all above prices at the publication time. All prices are in US dollars, subject to fluctuation and, if it isn't noted, will include additional fees at checkout.) Vivid Seats is a verified secondary market ticketing platform, and prices may be higher or lower than face value, depending on demand. They offer a 100% buyer guarantee that states your transaction will be safe and secure and your tickets will be delivered prior to the event. Still curious about Vivid Seats? You can find an article from their team about why the company is legit here. Metropolitan Opera House 2025 calendar Once the ABT closes up shop at the Metropolitan Opera House, the lights won't go down on the 3,800-seat venue. Here's what next there from July through December: About the American Ballet Theatre shows As noted above, there are five productions running at the Metropolitan Opera House over the next month. Here's a quick synopsis of each to make sure you're up to speed. 'Woolf Works' re-creates the emotions, themes, and fluid style of three of Virginia Woolf's novels: 'Mrs. Dalloway,' 'Orlando' and 'The Waves.' The show brings Woolf's world of 'granite and rainbow', where human beings are at once both physical body and uncontained essence to life. 'Giselle' is considered ballet's ultimate tale of unrequited love, heartbreaking loss, and triumphant forgiveness. The ballet tells the story of the titular village maiden and a handsome villager named Albrecht. What Giselle does not know is that her new paramour is actually a young nobleman in disguise who is already betrothed to another. 'Sylvia' brings Frederick Ashton's 1952 imagining of Louis Merante's 1876 three-act ballet to the stage. A mortal shepherd happens upon a woodland creature dance before interrupting the fun. He meets the huntress Sylvia. Mishaps lead to a kidnapping and quest to pair up once again after their chance meeting. 'The Winter's Tale' follows King Leontes of Sicilia who becomes consumed by envy when his friend, King Polixenes of Bohemia, visits him and his wife Hermione. A marriage is destroyed, a child is abandoned, and hope lives on within two lovers. 'Swan Lake' just might be the quintessential ballet. Featuring the unforgettable corps de ballet moving in magical unison as the majestic, glimmering swans, this romantic fable of dreamlike transformation, set to Tchaikovsky's glorious score, inspires awe and wonder. Other sophisticated 2025 NYC shows There's quite a bit of culture to experience all over the Big Apple these next few months. After digging through listings, here are five of the most exciting and nourishing artistic venues hosting events you won't want to miss live in the near future. • Carnegie Hall • Beacon Theatre • David Geffen Hall • Kings Theatre • Town Hall Want to catch a Broadway show? Check out our comprehensive list of all the best prices on tickets for 2025 Tony nominees to find the musical or play for you. This article was written by Emma Sutton-Williams, New York Post Commerce Writer/Reporter and resident fashionista. Emma is one of the best-dressed ladies in The Post's office, and also known for finding an unbelievable deal on any one of her stylish outfits. Divulging on everything from the most-popular and most-underrated purse brands to her honest thoughts on Kim Kardashian's Skims undergarments and apparel, Emma has cultivated an eye for style and an expertise for identifying the clothes and accessories worth your coin. At the same time, she proudly models the products she picks so you can see their fit and function first-hand. Emma has been creating shopping guides for The Post since 2024, and previously held bylines in Rolling Stone, Oprah Daily, Parents, InStyle, StyleCaster and more.
Zawya
4 days ago
- Business
- Zawya
Thawani Pay launches in-app electronics store with flexible installment plans from National Finance Company
Muscat: Reaffirming its commitment to enriching the everyday financial experiences of its users, Thawani has announced the launch of Thawani Store—a newly integrated feature within the Thawani app. To mark this milestone, the company has entered a strategic partnership with the leading financing provider, National Finance to offer seamless and swift device financing solutions and Adhwa Al Billa Technology (ABT) to supply mobile and electronic devices. In its initial phase, the collaborative initiative enables customers to purchase mobile phones of their choice, with laptops and a wider range of electronic devices soon to be available through the Thawani Store. Representing a strategic advancement in the company's digital ecosystem, Thawani Store reflects the brand's ongoing mission to deliver innovative, user-centric solutions that transcend conventional payment services. This feature grants users' access to a curated selection of electronic products from a single vendor through a unified interface that ensures seamless purchases and timely delivery. The service also enables customers to choose between full upfront payment or a flexible microfinancing through National Finance Company's plan, thereby enhancing affordability and convenience. Commenting on the launch, Majid Al Amri, Founder and CEO of Thawani, stated: 'At Thawani, we are constantly reimagining how technology can simplify lives and elevate consumer choice. More than a retail feature, the Thawani Store is a step towards embedding commerce within digital finance, where convenience, transparency, and control converge. By integrating shopping and financing within a single digital touchpoint, we are empowering users with the freedom to shop on their terms while keeping their financial well-being at the core. This launch reinforces our long-term strategy of integrating value-added services into our ecosystem, broadening our platform's utility while driving deeper engagement across Oman's evolving digital economy.' With a strategic focus on partnering with entities that mirror its commitment to quality, reliability, and customer-centricity, Thawani has joined forces with industry leaders and Adhwa Al Billa to power the Thawani Store experience. Adhwa Al Billa ensures product authenticity, consistent availability, and timely fulfilment, while National Finance facilitates structured installment plans over one- and two-year tenures, enabling customers to make high-value purchases with ease and confidence, without the constraints of traditional credit mechanisms. Through this collaboration with National Finance, a leading name in consumer finance, the Thawani Store delivers a fully digital, 24/7 shopping experience that is both accessible and affordable. Together, these collaborations exemplify Thawani's ecosystem-driven approach, seamlessly integrating retail and finance to deliver a unified, value-enhancing digital journey. Tariq Al Farsi, CEO of National Finance, commented, 'At National Finance, our priority has always been to enable greater financial access and flexibility for our customers through smart, sustainable financing solutions. Our collaboration with Thawani on the Thawani Store underscores our shared vision of democratizing digital finance and simplifying everyday purchases. By offering seamless installment plans within the app, we are contributing to a smooth shopping experience that meets the needs of today's digitally savvy consumers.' Faris Al Juma, CEO of Adhwa Al Billa Technology LLC, stated, 'We are proud to partner with Thawani in bringing this innovative digital retail experience to life. Our role is to ensure that customers enjoy reliable access to high-quality electronic products, delivered with speed and care. This collaboration aligns with our mission to be at the forefront of digital commerce in Oman by combining operational excellence with forward-thinking partnerships that truly enhance the customer journey.' The introduction of the Thawani Store marks a significant milestone in the company's broader strategy to expand its suite of integrated services within its digital infrastructure. As Thawani continues to evolve into a holistic, multi-vertical fintech platform, this latest offer reinforces its long-term commitment to scalable, user-centric innovations that meet the demands of an increasingly connected and convenience-oriented consumer landscape.
Cision Canada
5 days ago
- Health
- Cision Canada
Abbott Receives Health Canada Authorization for Whole Blood Rapid Test to Help Assess Suspected Concussions Français
The test, run on Abbott's portable i-STAT ® Alinity ® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), otherwise known as concussion The test produces lab-quality results in 15 minutes Clinicians can get a result at the patient's bedside, making the test accessible at urgent care clinics and healthcare settings outside of the hospital emergency room The test can be used to help evaluate patients up to 24 hours after injury MISSISSAUGA, ON, June 16, 2025 /CNW/ -- Abbott (NYSE: ABT) announced today that Health Canada has approved the company's i-STAT TBI test cartridge for use with whole blood, helping clinicians to assess suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes. Previously, the tests used to help assess mild traumatic brain injury (mTBI) were only authorized for use with plasma or serum, requiring samples to be sent to a lab for processing. This new authorization will enable testing to be performed in an array of new healthcare settings beyond hospital emergency departments, including urgent care clinics. This is an important step toward a future where testing could be done in settings such as in pharmacies, clinics without radiology or even in locations such as the sidelines of a sporting event. "Particularly in the emergency setting, we have long needed a reliable and expedient way to assess and triage patients for urgent computed tomography (CT) imaging of the brain after head trauma," said Andrew Beckett, M.D., a trauma surgeon and medical director of the Trauma Program at St. Michael's Hospital, Unity Health Toronto, and an associate professor at the University of Toronto. "The availability of a rapid point of care and objective test for traumatic brain injury will be a major advancement in emergency care as it can help facilitate immediate and precise diagnosis, ensuring prompt, appropriate treatment." The whole blood test on a portable instrument helps clinicians evaluate patients 18 years of age and older who present with suspected mTBI, commonly known as a concussion. Test results can help rule out the need for a CT scan of the head and assist in determining the best next steps for patient care in conjunction with other clinical information. The ability to perform the test with a whole blood sample means testing can take place in healthcare settings without a lab, which helps to accelerate head trauma evaluation. With this authorization, the i-STAT TBI test cartridge can be used to help evaluate patients up to 24 hours after injury, an important advancement since those injured often wait to seek care. It is estimated that 165,000 Canadians will experience a TBI this year. 1 Likewise, each year in Canada, more than 20,000 people are hospitalized for TBI, which can range from mild to severe and include concussions. 2 Among all types of TBIs, concussions are the most common, accounting for approximately 80 to 95 percent of such injuries. 3 Even a mild form of TBI can have long-term consequences. 2 For decades, standard TBI assessment has remained the same, with doctors leveraging tools such as the Canadian CT Head Rule which uses the Glasgow Coma Scale, a subjective assessment as well as CT scans, to detect brain tissue damage or lesions. A blood test provides objective information and helps remove the ambiguity of a standard concussion assessment. "Abbott has pioneered breakthroughs in TBI testing technology for more than a decade," said Beth McQuiston, M.D., senior medical director in Abbott's diagnostics business. "We're proud of this important step forward in advancing the standard of care for concussions. With this approval, right from the patient's bedside, clinicians are now able to order a rapid blood test that can provide powerful objective information, quickly. This dramatically changes the efficiency in the emergency room and helps optimize patient care." This approval expands Abbott's TBI test on market offerings, which already includes the i-STAT TBI Plasma test and the ARCHITECT ® and Alinity i lab test (serum and plasma). How the test works: The i-STAT TBI test cartridge with the i-STAT Alinity System requires a small venous blood sample – just a few drops applied to the test cartridge. The cartridge is then inserted into the portable i-STAT Alinity instrument. The test measures two brain-specific biomarkers that are released into the blood stream when there is a significant brain injury. If neither of these biomarkers measured are above an established cutoff, a significant injury has likely not occurred, and a CT scan can likely be avoided. Testing for these two biomarkers – ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) – following an injury can provide essential and objective information about a patient's condition and can help healthcare providers decide an appropriate treatment plan. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at and on LinkedIn, Facebook, Instagram, X and YouTube. The i-STAT TBI test cartridge was developed with support by the U.S. Department of Defense U.S. Army Medical Research and Development Command's (USAMRDC) U.S. Army Medical Materiel Development Activity (USAMMDA). The USAMRDC has been dedicated to developing a solution for the objective detection and evaluation of TBI for more than two decades and has played a critical role in developing the TBI test on Abbott's i-STAT Alinity platform. (Reference to USAMRDC and USAMMDA does not imply or constitute endorsement by these organizations or by the Department of Defense or the U.S. Army.) The T ransforming R esearch and C linical K nowledge in T raumatic B rain I njury (TRACK-TBI) research team was the first to demonstrate how this TBI blood test can be used for the benefit of TBI patients in clinical care. 1 Brain Injury Canada. Statistics: Traumatic brain injury (TBI) general statistics. Available at Accessed on April 29, 2025. 2 Government of Canada. Injury in review, 2020 edition: Spotlight on traumatic brain injuries across the life course. Available at Accessed November 2024. 3 Statistics Canada. Self-reported concussions in Canada: A cross-sectional study. Available at Accessed November 2024.
